Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1601 - 1625 of 2011 in total
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
Edotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.
Investigational
Matched Iupac: … [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²² …
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-2,4,6,8,10,12,14,16(23),17,19,21(24)-undecaene-2,23-bis ... 10,15-bis(1-sulfanylethyl)-2lambda5,22,23lambda5,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
Rosnilimab is under investigation in clinical trial NCT06041269 (A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)).
Investigational
Camoteskimab is under investigation in clinical trial NCT06436183 (A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis).
Investigational
AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).
Investigational
CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Investigational
R3R01 is an investigational lipid-modifying drug.
Investigational
Experimental
Matched Iupac: … 15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.0^{2,10}.0^{4,8}.0^{13,18}]icosa-1(12),2(10),3,8,13,15,17,19 …
Investigational
CA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. It is converted by cellular esterases to CA-074.[A258234,A258239]
Experimental
Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Investigational
Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy).
Investigational
Investigational
Matched Iupac: … {2,9}.0^{5,7}.0^{9,11}.0^{14,18}]icos-14(18)-en-8-yl]oxy}methoxy)phosphonic acid ... 4S,5S,7S,8R,9R,11S,13S)-1-methyl-17-oxo-7-(propan-2-yl)-3,6,10,16-tetraoxaheptacyclo[11.7.0.0^{2,4}.0^ …
TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to...
Investigational
Matched Description: … investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
GC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov...
Experimental
Matched Description: … These results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19. …
Matched Categories: … Experimental Unapproved Treatments for COVID-19
A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]
Illicit
Vet approved
Matched Iupac: … 15R,16R)-3-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹² …
Experimental
Matched Iupac: … 3-(2-hydroxyethyl)-20-(propan-2-yloxy)-3,13-diazahexacyclo[14.8.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22 …
Investigational
Experimental
Matched Iupac: … 1lambda4-thia-2,3,4,5-tetracupratetracyclo[2.1.0.0^{1,3}.0^{2,5}]pentane …
Investigational
A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]
Experimental
Illicit
Matched Iupac: … (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10 …
Experimental
Matched Iupac: … (4R,6R,8R,9Z,11E)-16-chloro-17,19-dihydroxy-4-methyl-3,7-dioxatricyclo[13.4.0.0^{6,8}]nonadeca-1(19), …
An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]
Investigational
Matched Iupac: … 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16) …
GS-441524 is an adenosine nucleotide analog antiviral, similar to remdesivir.[A203057,L13239] This molecule was patented in 2009. In vitro studies of GS-441524 have determined it has a higher EC50 than remdesivir against a number of viruses, meaning GS-441524 is less potent.[A203057,A203057] GS-441524 continues to be studied in the treatment of Feline...
Experimental
Matched Categories: … Experimental Unapproved Treatments for COVID-19
Displaying drugs 1601 - 1625 of 2011 in total